Technology Innovation Institute (TII) and Burjeel Medical City (BMC) are partnering to develop novel immunotherapy solutions for cancer treatment, focusing on T-cell based therapeutics like CAR-T and TIL therapy. In the first phase, TII will construct a computational platform to identify patient-specific antigens from single-cell transcriptomics data, enabling the design of CAR-T cells. The two-year partnership aims to boost the body's immune system to fight cancer and personalize cancer therapies using TII's technologies. Why it matters: This collaboration signifies the UAE's commitment to advancing cancer care through collaborative research and innovative solutions, potentially establishing the country as a leader in personalized oncology treatments.
The Russian Immune Diversity Atlas project aims to profile immune cells from people of different ancestries at a multiomics level. The goal is to reconstruct a reference atlas of the healthy immune system and investigate its perturbations in Type II Diabetes (T2D). The project seeks to identify novel mechanisms and genetic/epigenetic markers for early T2D diagnostics, prognosis, and therapy as part of the international Human Cell Atlas. Why it matters: Addressing genetic diversity in biomedical research, particularly in the context of the Human Cell Atlas, is crucial for personalized medicine and ensuring that treatments are effective across diverse populations in the Middle East and globally.
Eran Segal from Weizmann Institute of Science presented The Human Phenotype Project, a large-scale prospective cohort with over 10,000 participants. The project aims to identify novel molecular markers and develop prediction models for disease onset using deep profiling. The profiling includes medical history, lifestyle, blood tests, and molecular profiling of the transcriptome, genetics, microbiome, metabolome and immune system. Why it matters: Such projects demonstrate the growing focus on personalized medicine in the region, utilizing advanced AI and machine learning techniques for disease prevention and treatment.
Professor Eran Segal presented The Human Phenotype Project, a longitudinal cohort study with over 10,000 participants. The project aims to identify molecular markers and develop prediction models for disease using deep profiling techniques including medical history, lifestyle, blood tests, and microbiome analysis. The study provides insights into drivers of obesity, diabetes, and heart disease, identifying novel markers at the microbiome, metabolite, and immune system level. Why it matters: Such large-scale phenotyping initiatives could inform personalized medicine approaches relevant to the Middle East's specific health challenges.